Clinical Cancer Research · 2020 · 52 citations · 49 references
Life SciencesImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyCancer ImmunotherapyImmunotherapy For Solid TumorsT Cell Responses To TumorsTargeted Cancer TherapyTumor AntigensTumor-associated AntigensCancer Cell LysisCell ActivationCell LysisHost Cell LysisProtein Binding In OncologyRodent Tumor ModelsTumor Antigen-based ImmunotherapyTumor-specific T Cell Activation
Abstract Purpose: Mesothelin (MSLN) is a glycophosphatidylinositol-linked tumor antigen overexpressed in a variety of malignancies, including ovarian, pancreatic, lung, and triple-negative breast cancer. Early signs of clinical efficacy with MSLN-targeting agents have validated MSLN as a promising target for therapeutic intervention, but therapies with improved efficacy are still needed to address the significant unmet medical need posed by MSLN-expressing cancers. Experimental Design: We designed HPN536, a 53-kDa, trispecific, T-cell–activating protein-based construct, which binds to MSLN-expressing tumor cells, CD3ϵ on T cells, and to serum albumin. Experiments were conducted to assess the potency, activity, and half-life of HPN536 in in vitro assays, rodent models, and in nonhuman primates (NHP). Results: HPN536 binds to MSLN-expressing tumor cells and to CD3ϵ on T cells, leading to T-cell activation and potent redirected target cell lysis. A third domain of HPN536 binds to serum albumin for extension of plasma half-life. In cynomolgus monkeys, HPN536 at doses ranging from 0.1 to 10 mg/kg demonstrated MSLN-dependent pharmacologic activity, was well tolerated, and showed pharmacokinetics in support of weekly dosing in humans. Conclusions: HPN536 is potent, is well tolerated, and exhibits extended half-life in NHPs. It is currently in phase I clinical testing in patients with MSLN-expressing malignancies (NCT03872206).
49
Single‐domain antibody fragments with high conformational stability
Mireille Dumoulin, Katja Conrath, Annemie Van Meirhaeghe et al. · Protein Science · 2002 · 626 citations · Full text
Pedram Argani, Christine A. Iacobuzio–Donahue, Byungwoo Ryu et al. · PubMed · 2001 · 578 citations